Ginkgo Bioworks Holdings Inc vs Vital Farms Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.08 (market cap $590.53M), while Vital Farms Inc trades at $13.72 (market cap $561.10M). The key difference: Ginkgo Bioworks Holdings Inc and Vital Farms Inc are close in size by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| DNA | VITL | |
|---|---|---|
Market Cap | $590.53M | $561.10M |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $52.41 |
52-Week Low | $5.48 | $8.28 |
Enterprise Value | $627.78M | $563.90M |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Vital Farms (VITL) trades at $12.78, down 1.31% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 15.44% ROE and attractive valuation ratios (P/E 12.59, P/S 0.76). Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while revenue grew to $759M in 2025. The stock faces headwinds from multiple class action lawsuits filed in May 2026, creating investor uncertainty despite analyst consensus favoring a buy rating.
The outlook remains cautiously optimistic with a $13.50 consensus price target offering 5.6% upside potential. Key opportunities include sustained profitability and market positioning in natural foods, while risks center on legal challenges and projected earnings volatility. Institutional sentiment leans bullish with no sell ratings, but negative cash flow trends require monitoring.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →